NASDAQ:SWTX - SpringWorks Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $95.20
  • Forecasted Upside: 18.81 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.78 (0.98%)
1 month | 3 months | 12 months
Get New SpringWorks Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SWTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SWTX

Average Price Target: $95.20
▲ +18.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SpringWorks Therapeutics in the last 3 months. The average price target is $95.20, with a high forecast of $124.00 and a low forecast of $50.00. The average price target represents a 18.81% upside from the last price of $80.13.


The current consensus among 4 investment analysts is to buy stock in SpringWorks Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021The Goldman Sachs GroupReiterated RatingBuy$112.00N/A
2/26/2021BarclaysBoost Price TargetOverweight$92.00 ➝ $105.00High
2/25/2021HC WainwrightBoost Price TargetBuy$101.00 ➝ $124.00High
1/22/2021BarclaysBoost Price TargetOverweight$83.00 ➝ $92.00High
1/19/2021HC WainwrightBoost Price TargetBuy$87.00 ➝ $101.00Low
12/28/2020HC WainwrightReiterated RatingBuy$73.00 ➝ $87.00N/A
12/17/2020JPMorgan Chase & Co.Boost Price Target$57.00 ➝ $85.00High
12/17/2020BarclaysBoost Price TargetPositive ➝ Overweight$70.00 ➝ $83.00Medium
10/29/2020HC WainwrightBoost Price TargetBuy$58.00 ➝ $73.00Medium
9/15/2020BarclaysBoost Price TargetOverweight$52.00 ➝ $55.00Low
8/17/2020WedbushReiterated RatingBuyHigh
8/13/2020BarclaysReiterated RatingBuyHigh
8/13/2020WedbushBoost Price TargetOutperform$48.00 ➝ $50.00High
8/6/2020HC WainwrightReiterated RatingBuy$58.00Medium
7/22/2020HC WainwrightReiterated RatingBuy$58.00High
7/14/2020HC WainwrightReiterated RatingBuy$58.00High
6/23/2020HC WainwrightReiterated RatingBuy$58.00Medium
5/13/2020WedbushBoost Price TargetOutperform$45.00 ➝ $48.00Medium
5/5/2020BarclaysInitiated CoverageOverweight$48.00Low
4/28/2020HC WainwrightReiterated RatingBuy$58.00High
4/14/2020HC WainwrightLower Price TargetBuy$60.00 ➝ $58.00High
3/19/2020HC WainwrightUpgradeNeutral ➝ BuyHigh
3/4/2020HC WainwrightDowngradeBuy ➝ Neutral$40.00High
2/3/2020HC WainwrightReiterated RatingBuy$40.00High
1/21/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00Low
1/13/2020CowenReiterated RatingBuyMedium
12/17/2019HC WainwrightReiterated RatingBuy$34.00High
12/10/2019HC WainwrightReiterated RatingBuy$34.00Low
12/4/2019HC WainwrightInitiated CoverageBuy$33.00High
10/8/2019The Goldman Sachs GroupInitiated CoverageBuy$37.00Medium
10/8/2019JPMorgan Chase & Co.Initiated CoverageOverweight$32.00Medium
10/8/2019CowenInitiated CoverageOutperformMedium
10/8/2019WedbushInitiated CoverageOutperform$33.00Medium
(Data available from 6/20/2016 forward)
SpringWorks Therapeutics logo
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $80.13
Low: $76.03
High: $81.40

50 Day Range

MA: $75.40
Low: $67.45
High: $85.55

52 Week Range

Now: $80.13
Low: $35.20
High: $96.48


753,611 shs

Average Volume

314,397 shs

Market Capitalization

$3.93 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of SpringWorks Therapeutics?

The following Wall Street research analysts have issued research reports on SpringWorks Therapeutics in the last year: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for SWTX.

What is the current price target for SpringWorks Therapeutics?

5 Wall Street analysts have set twelve-month price targets for SpringWorks Therapeutics in the last year. Their average twelve-month price target is $95.20, suggesting a possible upside of 18.8%. HC Wainwright has the highest price target set, predicting SWTX will reach $124.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $50.00 for SpringWorks Therapeutics in the next year.
View the latest price targets for SWTX.

What is the current consensus analyst rating for SpringWorks Therapeutics?

SpringWorks Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SWTX will outperform the market and that investors should add to their positions of SpringWorks Therapeutics.
View the latest ratings for SWTX.

What other companies compete with SpringWorks Therapeutics?

How do I contact SpringWorks Therapeutics' investor relations team?

SpringWorks Therapeutics' physical mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company's listed phone number is 203-883-9490 and its investor relations email address is [email protected] The official website for SpringWorks Therapeutics is